Evidence map›Paper›PMID 36658533›Full record

ArticleBMC infectious diseases2023

Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment.

Yuka Torii, Ichiro Morioka, Yasumasa Kakei, Kazumichi Fujioka, Yu Kakimoto, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Akira Oka, Yoshinori Ito

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 1 country.

Yuka ToriiDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Ichiro MoriokaDepartment of Pediatrics and Child Health, Nihon University School of Medicine, 30-1 Oyaguchi, Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Yasumasa KakeiClinical and Translational Research Center, Kobe University Hospital, Kobe, 650-0017, Japan.
Kazumichi FujiokaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan.
Yu KakimotoDepartment of Pediatrics, The University of Tokyo, Tokyo, 113-8655, Japan.
Naoto TakahashiDepartment of Pediatrics, The University of Tokyo, Tokyo, 113-8655, Japan.
Tetsushi YoshikawaDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, 470-1192, Japan.
Hiroyuki MoriuchiDepartment of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan.
Akira OkaDepartment of Pediatrics, The University of Tokyo, Tokyo, 113-8655, Japan.
Yoshinori ItoDepartment of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan. ito.yoshinori@nihon-u.ac.jp.
Nihon University · JPThe University of Tokyo · JPFujita Health University · JPKobe University · JPKobe University Hospital · JPNagasaki University · JPNagoya University · JPSaitama Children's Medical Center · JP

Funding

Japan Agency for Medical Research and Development JP19gk0110037
6 · The paper itself

Abstract

backgroundCongenital cytomegalovirus (CMV) infection (cCMV) can cause sensorineural hearing loss and neurodevelopmental disabilities in children. Oral valganciclovir (VGCV) therapy has been reported to improve long-term audiological and neurodevelopmental outcomes in patients with cCMV. The levels of CMV DNA in whole blood have been monitored in previous studies. However, quantitative methods using whole blood have not been standardized. Recently, the plasma viral load has been standardized and widely used in CMV-associated diseases.

methodsCMV viral loads in whole blood and plasma were serially measured in 24 patients with a confirmatory diagnosis of cCMV during oral VGCV therapy using an in-house real-time PCR assay. Plasma samples were assayed using the Cobas 6800 system (Roche Diagnostics) in addition to an in-house assay.

resultsPlasma CMV viral loads were remarkably decreased at the end of therapy compared to before therapy. A significant correlation of CMV levels between whole blood and plasma was observed (Spearman's ρ = 0.566). The levels of CMV DNA before therapy were significantly correlated with the period of decreasing the viral loads to below the detection limit, not only in whole blood (Spearman's ρ = 0.901) but also in plasma (Spearman, ρ = 0.804). Finally, CMV viral loads between the in-house assay and commercially available standardized assay in 75 plasma samples with positive PCR results for CMV were compared; a significant correlation was observed between the results of both assays.

conclusionsThere was a significant correlation between the two assays (Spearman, ρ = 0.882), suggesting that CMV plasma viral loads measured by the standardized assay are widely used to monitor the levels of CMV DNA in patients with cCMV during oral VGCV therapy.

Indexed as

CytomegalovirusCytomegalovirus InfectionsChildDNA, ViralHumansReal-Time Polymerase Chain ReactionValganciclovirViral LoadDNA, ViralValganciclovirCongenital CMV infectionPCRPlasmaValganciclovirWhole blood

Identifiers

PMID36658533
PMCPMC9850601
OpenAlexW4317425883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.